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 Rosacea is a common inflammatory disorder that af­
fects both genders and most commonly presents on the 
central face [1]. The prevalence of rosacea has been esti­
mated in epidemiologic studies from selected populations; 
suffice it is to say that it is a very common disorder that 
presents regularly in dermatology and primary care clinics 
[1]. Although reported to most commonly affect individuals 
with facial skin rated as fitzpatrick Skin Type I­II, rosacea 
can affect people of any race, skin color, and creed. The 
published frequency of rosacea derived from patient visit 
data collected over a fifteen year period at a large practice 
in the united Kingdom reported an incidence of 1.65 per 
1000 person­years, with patients >30 years of age repre­
senting over 80% of the rosacea cases that were encoun­
tered [3]. 
Clinical Manifestations of Rosacea
Rosacea usually manifests clinically in the third to 
fourth decade of life. The earliest feature is often char­
acterized to be a transient “flushing” which reflects an 
acute­subacute vasodilation of central facial vasculature 
that subsides without any other visible features of rosa­
cea, thus confounding the ability to diagnose the disorder 
at this early time point. The usual clinical course of rosa­
cea is typified by periods of exacerbation of visible signs 
and symptoms followed by variable durations of remission. 
Over time, there are clinical manifestations of rosacea that 
are present during flares and some that persist between 
flares, thus making it easier to make a correct diagnosis of 
rosacea. The clinical presentations of rosacea and its clini­
cal course vary from patient to patient and may change 
over time [2, 4­7]. 
It is important for the clinician to appreciate and dif­
ferentiate that some clinical facial manifestations of ro­
sacea are intermittent (transient), occurring during a ro­
sacea flare, and others are permanent (non­transient), 
present both during and between flares (figure 1). The 
visible features of rosacea that are present intermittently 
(i.e. during a flare) are increased central facial erythema 
due to vascular dilatation (flushing of rosacea) that oc­
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curs in the vast majority of patients, and papulopustular 
lesions, that occur on the inner cheeks, central forehead 
and/or chin in a defined subset of patients [1, 2, 4­9]. 
Papules and pustules are often described as the inflam­
matory lesions of rosacea, and when present as visible 
findings, they are intermittent, as they emerge during a 
rosacea flare and resolve as the rosacea flare dissipates 
[1, 2, 4­6]. The predominant permanent visible manifes­
tation that persist between flares is non­transient central 
facial erythema, referred to as background erythema, 
that is diffuse, macular, usually confluent, and some­
times associated with soft edema, and associated facial 
telangiectasias, that are linear, and often very fine in ap­
pearance, or some can individually be thicker and more 
defined (figure 2) [2, 4­9]. Phymatous proliferations, 
which represent confluent sebaceous hyperplasia some­
times with mucinous and fibrous changes, occur most 
often on the nose (rhinophyma), are permanent findings 
[2, 4, 7]. 
The visible patterns of rosacea have been defined as 
subtypes to differentiate clinically with correlations of sub­
set presentations to approaches to management [2, 4­6, 
10]. The frequency of rosacea patients with central facial 
erythema only, which is designated as erythematotelan­
giectatic rosacea (subtype 1), is reported to be four­fold 
higher compared to patients presenting with papulopustu­
lar rosacea (subtype 2) [1, 2, 4]. Phymas have been esti­
mated to affect from 1­4% of individuals with rosacea, and 
are seen more often in men [1, 2, 4­7]. 
Clinical Course of Rosacea and Current Rosacea 
Assessment
At its initial onset, rosacea commonly presents as tran­
sient bouts of central facial flushing caused by vasodilation 
and increased blood flow which is most dominant on the 
central face [2, 4, 7­9]. As described above, after the va­
sodilation that causes the flushing resolves, the facial skin 
visibly appears normal [4­8]. As bouts of central facial flush­
ing repeatedly exacerbate and remit over time, the facial 
vasculature progressively becomes dilated and enlarged 
and also proliferates, leading to the emergence of non­tran­
sient background erythema and telangiectasias; both back­
ground erythema and telangiectasias are present between 
flares and persist between the flares [2, 5, 6­10]. 
ultimately, the optimal management of rosacea war­
rants the static evaluation of the visible manifestations 
that are present in the individual patient at a given point 
in time [1, 5, 6, 10]. At the time of presentation, the cur­
rent assessment of rosacea depends on (1) if the condi­
tion is flared or in remission; (2) if papulopustular lesions 
are present during a flare; (3) if phymatous changes are 
present; (4) the visible intensity of background erythema; 
(5) the magnitude, size, and pattern of telangiectasias; (6) 
if rosacea dermatitis is clinically apparent; and (7) if as­
sociated symptomatology is present (discussed below). As 
increased central facial transepidermal water loss (TEwL) 
and decreased stratum corneum water content (hydra­
tion) have been shown to be present in rosacea, especially 
during a flare, visible pink erythema and diffuse fine facial 
Figure 1. Clinical Manifestations of Cutaneous Rosacea
INTERMITTENT
Present during flares
Absent between flares
• Subacute/Acute Vasodilation (flushing)
• Inflammatory Lesions
• Papules
• Pustules
• Lesional/Perilesional erythema
• Diffuse Central Facial Erythema  
• Related to flushing and acute inflammation of 
rosacea and NOT related to chronically enlarged 
superficial dermal blood vessels
PERSISTENT
Present during and between flares
• Diffuse Central Facial Erythema 
• Related to chronically enlarged superficial dermal 
blood vessels* 
• Telangiectasias
• Phymatous changes
* Increases in magnitude during a flare of rosacea
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scaling may be noted, and has been described as rosacea 
dermatitis [5, 6, 10, 11]. 
As referred to earlier, rosacea has been classified us­
ing subtype designations that were published in 2002 [4]. 
A series of more recent publications from the American 
Acne & Rosacea Society have stressed the clinical rel­
evance of defining the visible manifestations in the indi­
vidual patient at the time of presentation. This allows for 
selection of a therapeutic approach that is targeted to treat 
the manifestations that are present in that patient, and not 
based solely on a irrespective of a subtype category [6, 
10, 13]. The two most commonly encountered presenta­
tions of rosacea are diffuse central facial erythema without 
papulopustular lesions and diffuse central facial erythema 
with papulopustular lesions (figure 3) [1, 2, 5, 6, 13]. Phy­
matous changes and/or ocular manifestations of rosacea 
can occur concurrently in patients with any presentation of 
rosacea [1, 2, 4, 5, 6, 7, 10, 13].
Symptomatology Associated With Rosacea
Episodic flushing during a rosacea flare is often associ­
ated with symptomatology. This includes a sensation of fa­
cial warmth. Symptoms of increased facial skin sensitivity, 
such as stinging, burning, tingling and pruritus are common, 
including when facial skin is contacted by several products 
commonly used for skin care and personal hygiene [1, 2, 
4­12]. Symptoms of skin sensitivity are more common and 
more severe during a rosacea flare, but may also be pres­
ent between flares in rosacea­prone skin [2, 5, 6, 10].
Rosacea Flares and Possible Triggers
The natural disease course of rosacea has not been 
well studied, yet it is known that rosacea­affected individu­
als experience episodic exacerbations that are character­
ized by specific clinical features. These are the following: 
(1) flushing of rosacea with increased facial erythema due 
to dilation of central facial vasculature; (2) augmented in­
flammation which translates visibly to increased facial ery­
thema; (3) soft central facial edema of variable magnitude; 
and (4) papulopustular lesions in some patients. Some of 
the triggers that have been noted to induce rosacea flares 
are ambient heat, hot liquids which cause oral­thermal 
flushing, spicy foods, and vasodilatory ingestants such as 
alcohol (e.g. red wine) and niacin [1, 2, 5­8, 10, 14­18]. 
Although not a mandatory pathogenic component of rosa­
cea, proliferation of Demodex mites can serve as a trig­
ger in some rosacea­prone patients through stimulation of 
specific inflammatory pathways [5, 19, 20]. Neurogenic, 
immunologic, and inflammatory pathways have been iden­
tified that appear to be operative in rosacea pathophysiol­
ogy; physiochemical and structural difference in rosacea­
affected skin as compared to normal skin have been re­
ported [5, 6, 15­18, 21­25].
Pathophysiologic Mechanisms in Rosacea and 
Clinical Relevance 
Publications devoted primarily to pathophysiology of 
rosacea appear elsewhere in the medical literature; nev­
ertheless, explanations of rosacea­prone skin and the 
basic pathophysiologic mechanisms that seem to be op­
erative in rosacea are necessary in order to better un­
derstand the direct correlations with specific signs and 
symptoms of rosacea and allow for more rational selec­
tion of individual therapies in each case that address spe­
cific clinical manifestations of rosacea [5, 6, 13, 22, 26­
32]. Rosacea­prone skin is characterized by three major 
Figure 2.
Background facial erythema of rosacea: а — persistent, non-transient with predominance of diffuse central facial 
erythema; telangiectasias present; b — persistent, non-transient with predominance of telangiectasias and mild 
diffuse central facial erythema
а b
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inherent components: (1) neurovascular dysregulation; 
(2) augmented immune detection and response; and (3) 
several physiochemical alterations that identified in the 
facial skin of rosacea­affected individuals as compared to 
normal facial skin of individuals without rosacea [5, 6, 15­
17, 33]. Essentially, rosacea­prone facial skin is “wired” 
to react to inciting factors that do not usually trigger an 
immunologic and/or inflammatory response in those 
without rosacea. Trigger that are recognized to induce 
rosacea flares (e.g. heat, uV light, spices) induce sev­
eral reactions in rosacea­prone skin. These include neu­
rogenic responses that cause vasodilation (flushing) and 
sensitive skin symptoms (stinging, burning, tingling) and 
cascade upregulation that increases antimicrobial pep­
tide production (especially cathelicidin (LL­37) and other 
variant pro­inflammatory peptides) that induce cutaneous 
inflammation and vasodilation during the flare; repeated 
episodes of cathelicidin production are also believed to 
increase the density and diameter of superficial vascu­
lature of central facial skin which progressively leads to 
non­transient facial erythema that is persistent between 
rosacea flares [2, 5­6, 8­10, 15­18, 21­28, 33]. current 
information related to the potential modes of action of 
specific therapies used to treat specific clinical features 
of rosacea appear to at least partially explain why certain 
therapeutic agents improve some visible signs of rosacea 
and not others [2, 5, 6, 10, 13, 26, 29, 31­35]. 
Conventional Medical Management of Rosacea
The majority of studies of medical therapies for ro­
sacea evaluate subjects with papulopustular lesions as 
a primary parameter, and also assess the associated 
lesional and perilesional erythema secondarily. To add, 
other than studies and reports with topical alpha­adren­
ergic agonists (e.g. bromonidine, oxymetazoline), none of 
the commonly used topical or oral therapies have dem­
onstrated efficacy for the background non­transient facial 
erythema that persists between flares [5, 6, 9, 13, 26, 31­
33, 36­38].
As no bacterium or microbe has been shown to be 
mandatory in the pathogenesis of rosacea, therapies 
which inhibit inflammatory pathways involved in rosacea 
have been central to therapy for papulopustular rosacea 
[2, 5, 6, 15­18, 21, 22, 27, 28, 39].
Figure 3. Common clinical presentations of cutaneous rosacea
DIFFUSE CENTRAL FACIAL ERYTHEMA
 WITH PAPULOPUSTULAR
LESIONS
WITHOUT PAPULOPUSTULAR 
LESIONS
DURING FLARE
Increased Facial  Blood Flow
“Acute” Vasodilation (Flushing)
[Neurosensory Dysfunction 
 Increased Neuropeptides
Augmented Innate Immunity 
Increased LL-37 
and Variant Peptides]
BETWEEN FLARES
Persistent Nontransient
Facial Erythema of Rosacea
Minimal  Severe
[Increased LL-37  
Increasesin VEGF  
Increase in Enlarged 
Dermal Vasculature]
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Proper Skin Care for Rosacea 
Although skin care products and methodology are not 
controlled in many rosacea studies, proper skin care is 
an integral part of the rosacea management plan for sev­
eral reasons [10­13, 35­38]. To summarize, using a prop­
erly selected gentle cleanser and moisturizer counteracts 
permeability barrier impairment when lessens signs and 
symptoms of facial skin irritation inherent to the disease 
or related to topical products applied to the skin. Photo­
protection is also very important in the management of ro­
sacea, as ambient heat and ultraviolet light are rosacea 
triggers, and chronic photodamage independently induces 
persistent erythema and telangiectasia in chronically ex­
posed skin [1, 2, 5, 10­13, 16, 18­35].
Overview of Topical Agents for Rosacea 
The most commonly used topical agents in the united 
States which are approved by the food & Drug Adminis­
tration (fDA) for papulopustular rosacea are metronida­
zole (Metro; 0.75% gel, cream, lotion; 1%; gel, cream), 
azelaic acid 15% (AzA; gel, foam), and ivermectin 1% 
cream (IVM) [31, 32, 36­38]. In papulopustular rosacea, 
these agents have been shown to significantly decrease 
papules, pustules, and lesional/perilesional erythema, the 
latter resolving as the papulopustular lesions remit. 
The mechanism of action of topical metronidazole in 
rosacea is unknown. Mechanisms which can reduce in­
flammation in rosacea have been suggested but data are 
limited [31, 32, 37, 38]. Research data, including studies 
completed in subjects with papulopustular rosacea dem­
onstrate that AzA reduces serine protease activity in rosa­
cea­affected central facial skin which leads to decreased 
cathelicidin (LL­37) production and reduction in inflamma­
tion [34, 41]. 
Although reported to be of benefit in some small studies 
and case reports, less clinical and basic science research 
data are available with other topical agents that have been 
used for rosacea, such as sulfacetamide 10%­sulfur 5% 
formulations, calcineurin inhibitors, and permethrin [5, 13, 
29, 31, 32, 36­38].
Overview of Oral Agents for Rosacea
The predominant oral therapeutic class that has been 
used for rosacea has been the tetracyclines, primarily oxy­
tetracycline, tetracycline, and doxycycline utilized for treat­
ment of papulopustular rosacea [31, 32, 36­38, 42]. Other 
oral antibiotics that have demonstrated efficacy for papulo­
pustular rosacea include metronidazole and azithromycin 
[31, 32, 36, 38, 42­44]. Interestingly, oral antibiotics have 
been used to treat rosacea for over five decades despite 
the lack of definitive evidence that a bacterium is a caus­
ative or mandatory component of the pathogenesis of ro­
sacea [2, 6, 16, 18, 21, 22, 30, 39].
It is believed that the biologic anti­inflammatory proper­
ties of tetracyclines that are unrelated to antibiotic activity 
are the major reason why these agents are of therapeu­
tic benefit for rosacea [30, 34, 45­47]. This concept is fur­
ther supported by several studies which demonstrate the 
effectiveness of subantimicrobial dose doxycycline (e.g. 
doxycycline hyclate 40 mg modified­release [MR] capsule 
once daily) in the treatment of papulopustular rosacea [30, 
42, 48­51]. Subantimicrobial dose doxycycline exhibits a 
pharmacokinetic profile that is devoid of antibiotic selection 
pressure, but retains anti­inflammatory activity including 
downregulation of the cathelicidin pathway, thus circum­
venting alteration of the host microbiome and the antibiotic 
resistance that are inevitable with oral antibiotic therapy 
[42, 48­52]. In the phase III pivotal trials completed with 
doxycycline MR 40 mg capsule once daily versus placebo, 
no cases of vaginal candidiasis or photosensitivity were 
observed in the active treatment group [50]. Doxycycline 
MR 40 mg capsule once daily has demonstrated efficacy 
equivalent to doxycycline 100 mg daily for papulopustular 
rosacea, with a significantly lower incidence of gastrointes­
tinal side effects [48]. Doxycycline 20 mg twice daily is also 
subantimicrobial, however, data are limited for treatment 
of rosacea, and anti­inflammatory activity is likely to be in­
adequate if there is incomplete adherence with twice daily 
use [42, 49, 52]. 
Oral isotretinoin may be effective in selected cases of 
recalcitrant papulopustular rosacea or in early phyma for­
mation that has not progressed to a mucinous or fibrotic 
phase [39, 42, 53]. unlike acne vulgaris, prolonged remis­
sions of rosacea do not occur after isotretinoin is discon­
tinued. 
More Recent Additions to the Medical Therapy Ar-
mamentarium for Rosacea 
Two topical therapies for rosacea that incorporate new 
active ingredients have emerged over the past three years. 
The first, brimoninide tartrate 0.5% (brimonidine 0.33%) 
gel is the first fDA­approved for treatment of persistent 
nontransient facial erythema of rosacea (background ery­
thema). The second, ivermectin 1% cream, is indicated for 
treatment of papulopustular rosacea. 
The Rationale for Topical α-Adrenergic Receptor 
Agonist Therapy in Rosacea 
central facial erythema that increases in visible intensity 
during flares and persists between flares is the primary di­
agnostic clinical feature of rosacea [2, 4, 5, 7, 14, 21, 26]. 
The increased intensity of erythema occurring during a flare 
reflects primarily vasodilation (flushing of rosacea). Impor­
tantly, multiple other processes contribute such as neuro­
genic inflammation, innate and acquired immunologic in­
flammation, lesional and perilesional erythema if papulopus­
tular lesions are present, and epidermal permeability barrier 
impairment causing increased TEwL [2, 5, 6, 8, 11, 14­18, 
21­28, 33]. However, the background erythema present be­
tween flares of rosacea correlates with the increased den­
sity and size of superficial dermal vasculature that remains 
physiologically vasoactive via sympathetic neural control, 
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and the presence of telangiectasias which are not vasoac­
tive [2, 5, 6, 9, 14, 16, 18, 21, 26, 33, 54, 55]. 
Topically applied α­adrenergic receptor agonists 
(α­agonist) are the first class of topical agents shown to 
decrease the background facial erythema of rosacea. Bri­
monidine tartrate has been evaluated most extensively, 
with oxymetazoline and xylometazoline also discussed in 
case reports [33, 37, 56­58]. The therapeutic target of an 
α­agonist are the α­adrenoreceptors present in the smooth 
muscle layer encasing the wall of superficial dermal blood 
vessels. These vessels function physiologically to modu­
late vascular tone and relative blood flow within the su­
perficial and deep plexuses of skin [26, 33]. The vasocon­
striction that occurs after facial application of an α­agonist 
leads to reduction in erythema which persists over the 
duration of adequate binding with the α­adrenoreceptors 
in the vessel walls. Smaller papillary vessels such capillar­
ies and telangiectasias do not vasoconstrict as they do not 
contain a fully formed smooth muscle sheath and hence, 
are not modulated by α­adrenergic control [26, 33, 56­58].
Topical Brimonidine for Non-Transient Erythema of 
Rosacea 
Brimonidine tartrate (BT) is an α­agonist with selectiv­
ity for α­2­adrenergic receptors [57]. A single application 
dose ranging study (n = 122) demonstrated that BT 0.5% 
gel (equivalent to brimonidine 0.33%) applied once daily 
exhibited the greatest effect on erythema reduction [57]. 
Pharmacokinetic analysis after application of BT gel to fa­
cial skin over 29 days compared to ocular application of 
BT 0.2% ophthalmic solution (used for open­angle glauco­
ma) showed a superior safety profile for BT 0.5% gel with 
low systemic exposure and no systemic drug accumula­
tion observed over the course of the study [59]. The phase 
III pivotal trials evaluated adults (n = 553) with background 
erythema of rosacea and a maximum of two papulopus­
tular lesions, with results consistent with those reported 
from a similarly designed phase II study (n = 269). Study 
outcomes demonstrated efficacy, favorable tolerability, a 
lack of systemic safety signals, absence of tachyphylaxis, 
and minimal potential for rebound with patients assessed 
at two weeks post­therapy [57, 60]. A 52­week open la­
bel, multicenter, evaluated BT 0.5% gel applied once daily 
in subjects with facial erythema of rosacea (n = 449) both 
with and without papulopustular lesions, with 29.2% of 
patients using concomitant topical (i.e. metronidazole, az­
elaic acid) or oral (i.e. tetracyclines) medications [61]. The 
long term data demonstrated that the efficacy of BT 0.5 
gel sustained over the duration of the study and that toler­
ability and safety was consistent with data from the phase 
II and phase III trials. 
Data from available studies demonstrate overall that 
BT 0.5% gel induces its onset of erythema reduction as 
early as 30 minutes, a peak effect at approximately 3 
hours, and a duration of peak erythema reduction of ap­
proximately 6 hours after a single application. As the peak 
effect wanes, the usual pattern of reappearance of ery­
thema was a progressive return of facial erythema over 2 
to 3 hours to a level that was slightly less than baseline, 
however, in some cases the intensity of erythema can ex­
ceed what was noted at baseline before application or a 
paradoxical increase in erythema may be observed occa­
sionally in some patients [57, 60]. Neither tachyphylaxis or 
worsening of papulopustular rosacea were observed in the 
long term study which included 335 subjects and 279 sub­
jects treated with BT 0.5% gel once daily for 6 months and 
12 months, respectively [61].
Safety assessments completed during the pivotal and 
long term studies with facial application of various concen­
trations of BT gel support an overall favorable safety profile 
with no systemic safety signals. BT 0.5% gel applied once 
daily for up to 52 weeks was associated with a cutaneous 
adverse event noted at some time in 105 subjects (23.4%), 
with worsening of erythema or rosacea, skin burning sen­
sation, skin irritation, pruritus, flushing, and allergic derma­
titis reported in 10.1%, 3.3%, 3.1%, 2.0%, 8.9%, and 1.6% 
of subjects, respectively.61 BT 0.5% gel was discontinued 
in 12.7% of subjects (n = 57) due to a cutaneous adverse 
event, which is not unexpected given the inherent vascular 
reactivity and skin sensitivity of rosacea and the potential 
for contact dermatitis in some patients. Sporadic cases of 
rebound erythema or paradoxical erythema with use of BT 
0.5% gel have been published, most likely due to interpa­
tient variability in vascular reactivity or confounding effects 
of exogenous rosacea triggers [62, 63]. It is recommended 
that clinicians and their staff inform patients that an in­
crease in facial redness may sometimes occur, and to use 
BT 0.5% gel only how it is recommended. 
Oxymetazoline, another α­agonist, is currently under 
research development in the uS. 
Topical Ivermectin for Papulopustular Rosacea 
Ivermectin (IVM) is a semisynthetic endectocide that 
is from the avermectin family of compounds. for over two 
decades, IVM has been utilized orally to treat a variety of 
endoparasitic infestations, and both orally and topically to 
treat exoparasitic infestations [64]. The antiparasitic activ­
ity of IVM is through blockade of specific channels involved 
in neural synapse transmission found in invertebrates (e.g. 
worms, mites, lice) that can infest mammals, including hu­
mans [62]. Oral administration of IVM has been reported 
to be effective for demodecidosis, and in patients with cu­
taneous and ocular findings related to Demodex folliculo­
rum proliferation [65, 66]. An increased density of facial D 
folliculorum has been demonstrated in some patients with 
both erythematotelangiectatic or papulopustular rosacea 
compared to facial skin of healthy controls, leading to stud­
ies of IVM cream in subjects with papulopustular rosacea 
[19, 20, 67]. As anti­inflammatory properties have been 
reported with IVM, the therapeutic activity of IVM may be 
related at least partially to these effects as Demodex prolif­
eration is not present in all cases of rosacea [67]. 
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IVM 1% cream applied once daily was shown to be su­
perior to vehicle cream once daily in subjects with moder­
ate to severe papulopustular rosacea in two randomized, 
controlled, pivotal trials (n = 1371). The mean inflamma­
tory lesion count at baseline in the two studies were 30.9 
(+/­ 14.33) and 32.9 (+/­ 13.70), which are markedly higher 
than baseline mean inflammatory lesion counts in studies 
of other fDA­approved drugs used to treat papulopustular 
rosacea.67 In both studies, a greater percentage of sub­
jects in the IVM 1% group achieved “treatment success”, 
defined as “clear” or “almost clear”, based on investigator 
global assessment, with outcomes of 38.4% and 40.1% , 
and 11.6% and 18.8%, in the IVM study arms and the vehi­
cle study arms, respectively (both p < 0.01). Inflammatory 
lesion count reductions compared to baseline was 76.0% 
and 75.0% in both IVM groups vs 50.0% for both vehicle 
groups, respectively, which was also significant [67]. The 
efficacy, safety, and tolerability assessments in pivotal 
and long term trials demonstrated the effectiveness of IVM 
1% cream, with a low incidence of cutaneous application 
site reactions (e.g. burning, pruritus; no serious adverse 
events, no significant systemic side effects, and absence 
of clinically significant laboratory abnormalities [67, 68]. A 
randomized controlled study of IVM 1% cream once daily 
(n = 478) versus Metro 0.75% cream twice daily (n = 484) 
for papulopustular rosacea demonstrated the superior ef­
ficacy of IVM 1% in reducing inflammatory lesions as early 
as week 3 and by investigator global assessments evalu­
ating treatment success (p < 0.001 for both) [69]. Addition­
ally, remission of rosacea after discontinuation of therapy 
lasted approximately 4 weeks longer with IVM 1% as com­
pared to Metro 0.75% cream [69]. 
Rosacea Management Recommendations: From 
the Benchtop to the Treatment Room
The following points summarize management recom­
mendations based on the above review and supporting 
references, designed to optimize medical treatment of the 
more common clinical presentations of rosacea: central fa­
cial erythema with papulopustular lesions (papulopustular 
presentation) and central facial erythema without papulo­
pustular lesions (erythematotelangiectatic presentation). 
  The first step in optimal management of rosacea after 
obtaining pertinent details of the patient’s history, 
is to assess the current visible and symptomatic 
manifestations that are present.
  control of the selection of skin care products and how 
they are integrated into the treatment regimen by the 
clinician is very important in all cases of rosacea. 
This supports use by the patient of a gentle cleanser 
and moisturizer which serves to reduce TEwL and 
symptoms of skin sensitivity, and decreases the 
potential for skin tolerability reactions related to 
medications and other products applied to rosacea­
affected facial skin [2, 6, 10­13, 21, 31, 32, 39].
  As best as is possible from a practical perspective, 
avoidance of known rosacea triggers is strongly 
recommended in the management of rosacea [1, 2, 4, 
5, 6, 31, 32, 39].
  Photoprotection, including avoidance of direct sunlight 
exposure as much as possible (especially during 
peak hours), and use of broad­spectrum sunscreen is 
strongly recommended. Avoidance of direct sunlight 
exposure and sunscreen use lessen the potential 
triggering effect of ultraviolet light on rosacea­prone 
facial skin. Avoidance of direct sunlight exposure, 
especially during peak hours, decreases the intensity of 
ambient heat which could otherwise serve as trigger for 
rosacea [1, 2, 6, 10­13, 31, 32].
  In patients with papulopustular rosacea, topical 
therapy, oral therapy, or a combination of both may be 
used, depending on severity. 
— If the papulopustular rosacea is mild to moderate 
in severity, topical therapy (e.g. Metro, IVM, AzA) 
alone is usually very effective in reducing inflam­
matory lesions and their associated erythema. 
Oral therapy with a tetracycline agent can also 
be used, with subantimicrobial dose doxycycline 
offering the major advantage of efficacy without 
emergence of antibiotic resistant bacteria [13, 
31, 36, 37, 39, 42, 48­51].
— for papulopustular rosacea rated in severity as 
moderate to severe, a combination of topical and 
oral therapy is commonly used to achieve con­
trol, usually followed within a few months (e.g. 
2­3 months) by transition to topical therapy alone 
to continue the suppression of rosacea and re­
duce the frequency and severity of rosacea 
flares. Alternatively, the pivotal trials and other 
studies of subantimicrobial dose doxycycline 
were completed as monotherapy, supporting its 
use over a longer duration when transcending off 
of initial combination therapy. If it is elected to uti­
lize topical therapy alone for papulopustular ro­
sacea that is within the higher range of moderate 
severity or is graded as severe, IVM 1% cream 
was studied in subjects with a higher baseline 
mean inflammatory lesion count (approximately 
30 lesions) than other agents for papulopustular 
rosacea (approximately 18 to 21 lesions) [31, 36, 
37, 42, 48­51, 67, 70].
— Once a flare of papulopustular rosacea is con­
trolled, background erythema which is non­tran­
sient and persistent often becomes more evi­
dent. Background erythema may be treated by 
the addition of an α­agonist such as BT 0.5% gel 
once daily. It is important that gentle skin care 
and photoprotection be continued and that trig­
gers be avoided. Telangiectasias that are both­
ersome to the patient may be treated with the 
appropriate laser and/or light modalities [13, 26, 
33, 35, 37, 42, 57­61].
39Обзор литературы
— If topical α­agonist therapy is initiated for papu­
lopustular rosacea before therapy is given to 
reduce inflammatory lesions, background ery­
thema will dissipate, but lesional­perilesional ery­
thema will initially persist as small red dots until 
the inflammatory lesions resolve [33, 37].
— Oral isotretinoin is reserved for selected cases of 
recalcitrant papulopustular rosacea. Once con­
trolled, low dose and intermittent dose regimens 
may be effective for long term management. 
Teratogenicity and potential side effects of oral 
isotretinoin therapy must be taken into consider­
ation both before and during use [42, 53]. 
  central facial erythema without papulopustular lesions 
may be managed medically by proper skin care, 
photoprotection, and application of an α­agonist, such 
as BT 0.5% gel. Physical modalities such as lasers 
(e.g. pulse dye laser [PDL]) and intense pulse light (IPL) 
can also be used for treatment of vascular erythema 
and telangiectasias. Oral agents have not been shown 
to be effective for persistent background erythema of 
rosacea [13, 26, 33, 35, 37, 42, 57­63].
  fully developed phymas require surgical intervention. 
Early phymatous changes may respond to oral 
isotretinoin therapy [31, 35, 39].
  Although the focus of this article is cutaneous 
rosacea, ocular rosacea is responsive to therapy 
with an oral tetracycline, especially oral doxycycline. 
Ophthalmologic consultation is clearly warranted if 
vision is impaired, if associated symptomatology is 
severe, or if refractory to oral tetracycline therapeutic or 
other therapeutic measures [31, 32, 39, 42]. 
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